{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T12:40:47Z","timestamp":1707136847037},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s00105-006-1182-z","type":"journal-article","created":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T14:51:17Z","timestamp":1153320677000},"page":"672-678","source":"Crossref","is-referenced-by-count":2,"title":["Ist der Psoriasis-Plaque-Test im Zeitalter der Biologics noch aktuell?","Is the psoriasis plaque test still relevant in the age of biologicals?"],"prefix":"10.1007","volume":"57","author":[{"given":"G.","family":"Wozel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1182_CR1","first-page":"2","volume":"41","author":"Behrendt","year":"1990","unstructured":"Behrendt H, Korting HC (1990) Klinische Pr\u00fcfung von erw\u00fcnschten und unerw\u00fcnschten topisch applizierbarer Glukokortikosteroide am Menschen. Hautarzt 41: 2\u20138","journal-title":"Hautarzt"},{"key":"1182_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000210775","volume":"1","author":"Berardesca","year":"1988","unstructured":"Berardesca E, Maibach HI (1988) Skin occlusion: treatment or drug-like device? Skin Pharmacol 1: 207\u2013215","journal-title":"Skin Pharmacol"},{"key":"1182_CR3","doi-asserted-by":"crossref","unstructured":"Bladon PT, Cooper NF, Wood EJ, Cunliffe WJ (1986) Biochemical markers in the mouse tail model of psoriasis. In: Marks R, Plewig G (eds) Skin models; models to study function and disease of skin. Springer, Berlin Heidelberg New York Tokyo, pp 172\u2013182","DOI":"10.1007\/978-3-642-70387-4_21"},{"key":"1182_CR4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0014-2964(74)90112-1","volume":"10","author":"Bollag","year":"1974","unstructured":"Bollag E (1974) Therapeutic effects of an aromatic retinoic acid analog on chemical induced skin papillomas and carcinomas of mice. Eur J Cancer 10: 731\u2013737","journal-title":"Eur J Cancer"},{"key":"1182_CR5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0738-081X(95)93819-A","volume":"13","author":"Christophers","year":"1995","unstructured":"Christophers E, Mrowietz U (1995) The inflammatory infiltrate in psoriasis. Clin Dermatol 13: 131\u2013135","journal-title":"Clin Dermatol"},{"key":"1182_CR6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2340\/00015555524348","volume":"52","author":"Dumas","year":"1972","unstructured":"Dumas KJ, Scholtz JR (1972) The psoriasis bio-assay for topical corticosteroid activity. Acta Dermatol Venereol 52: 43\u201348","journal-title":"Acta Dermatol Venereol"},{"key":"1182_CR7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1067\/mjd.2000.105561","volume":"42","author":"Geilen","year":"2000","unstructured":"Geilen CC, Mrowietz U (2000) Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris. J Am Acad Dermatol 42: 837\u2013840","journal-title":"J Am Acad Dermatol"},{"key":"1182_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/000155556215","volume":"62","author":"Lindberg","year":"1982","unstructured":"Lindberg M, Johannesson A, Forslind B (1982) The effect of occlusive treatment on human skin. An electron microscopic study on epidermal morphology as affected by occlusion and dansyl chloride. Acta Dermatol Venereol 62: 1\u20135","journal-title":"Acta Dermatol Venereol"},{"key":"1182_CR9","unstructured":"Maibach HI, Lowe NJ (1985) Models in Dermatology 2, dermatopharmacology and toxicology. Karger, Basel M\u00fcnchen Paris London New York Tokyo Sydney"},{"key":"1182_CR10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2133.1981.tb01020.x","volume":"105","author":"Marks","year":"1981","unstructured":"Marks J, Rogers S, Chadrik B, Shuster S (1981) Clearance of chronic plaque psoriasis by anthralin \u2013 subjective and objective assessment and comparison with photochemotherapy. Br J Dermatol 105: 96\u201399","journal-title":"Br J Dermatol"},{"key":"1182_CR11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/archderm.1989.01670140087017","volume":"125","author":"Marks","year":"1989","unstructured":"Marks R, Barton SP (1989) Assessment of disease progress in psoriasis. Arch Dermatol 125: 235\u2013240","journal-title":"Arch Dermatol"},{"key":"1182_CR12","doi-asserted-by":"crossref","unstructured":"Mehlis S, Gordon KB (2004) From laboratory to clinic: rationale for biologic therapy. In: Menter A, Cather J (eds) Dermatologic clinics \u2013 psoriasis. Saunders. Philadelphia London Toronto Montreal Sydney Tokyo, pp 371\u2013377","DOI":"10.1016\/S0733-8635(03)00124-4"},{"key":"1182_CR13","unstructured":"McCullough JL, Weinstein GD, Ziboh VA (1985) Cell kinetics in psoriasis. The use of animal and human skin models. In: Maibach HI, Lowe NJ (eds) Models in dermatology. Karger, Basel, pp 51\u201358"},{"key":"1182_CR14","unstructured":"Moon RC (1993) Retinoids in experimental oncology. In: Hong WK, Lotan R (eds) Retinoids in oncology. Marcel Dekker, New York Basel Hong Kong, pp 109\u2013125"},{"key":"1182_CR15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1365-2133.1998.02554.x","volume":"139","author":"Mrowietz","year":"1998","unstructured":"Mrowietz U, Graeber M, Br\u00e4utigam M, et al. (1998) The novel ascomycin derivative SDZ AASM 981 is an effective anti-psoriatic compound when used topically under occlusion. Br J Dermatol 139: 992\u2013996","journal-title":"Br J Dermatol"},{"key":"1182_CR16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2133.1988.tb03237.x","volume":"119","author":"Newton","year":"1988","unstructured":"Newton JA, Boodle KM, Dowd PM, Greaves MW (1988) Topical NDGA (nordihydroguaiaretic acid) in psoriasis. Br J Dermatol 119: 404\u2013406","journal-title":"Br J Dermatol"},{"key":"1182_CR17","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/archderm.1987.01660350099022","volume":"123","author":"Nieboer","year":"1987","unstructured":"Nieboer C, Bruynzeel DP, Boorsma DM (1987) The effect of occlusion of the skin with transdermal therapeutic system on Langerhans cells and in the induction of skin irritation. Arch Dermatol 123: 1499\u20131502","journal-title":"Arch Dermatol"},{"key":"1182_CR18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.0906-6705.2005.00350.x","volume":"14","author":"Radeke","year":"2005","unstructured":"Radeke HH, Ludwig RJ, Boehncke WH (2005) Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo. Exp Dermatol 14: 641\u2013666","journal-title":"Exp Dermatol"},{"key":"1182_CR19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nm1162","volume":"11","author":"Sano","year":"2004","unstructured":"Sano S, Chan KS, Carbajal S et al. (2004) Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11: 43\u201349","journal-title":"Nat Med"},{"key":"1182_CR20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/000155598442818","volume":"78","author":"Savolainen","year":"1998","unstructured":"Savolainen L, Kontinen J, Alatalo E et al. (1998) Comparison of actual psoriasis surface area and the psoriasis area index by the human eye and machine vision methods in following the treatment of psoriasis. Acta Dermatol Venereol 78: 466\u2013467","journal-title":"Acta Dermatol Venereol"},{"key":"1182_CR21","unstructured":"Schaefer H, Redelmeier TE (1996) Skin barrier \u2013 principles of percutaneous absorption. Karger, Basel Freiburg Paris London New York New Delhi Bangkok Singapore Tokyo Sydney"},{"key":"1182_CR22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1523-1747.1999.00538.x","volume":"112","author":"Sch","year":"1999","unstructured":"Sch\u00f6n MP (1999) Animal models in psoriasis \u2013 What can we learn form them? J Invest Dermatol 112: 405\u2013410","journal-title":"J Invest Dermatol"},{"key":"1182_CR23","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","volume":"352","author":"Sch","year":"2005","unstructured":"Sch\u00f6n MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352: 1899\u20131912","journal-title":"N Engl J Med"},{"key":"1182_CR24","unstructured":"Van de Kerkhof, Salonen SH (2003) Large-scale European survey of quality of life in patients with psoriasis: second phase results on quality of life and treatment reported by 7,525 members of European Psoriasis Patient Associations.http:\/\/www.psori.fi\/doc\/patient_survey_2nd_phase(2003).pdf"},{"key":"1182_CR25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1468-3083.2005.01322.x","volume":"20","author":"Van","year":"2006","unstructured":"Van Duijnhoven MW, K\u00f6rver JE, Vissers WH et al. (2006) Effect of calcipotriol on epidermal cell populations in alefacept-treated psoriatic lesions. J Eur Acad Dermatol Venereol 20: 27\u201333","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1182_CR26","unstructured":"Van Scott EJ (1986) Lesional heterogeneity in psoriasis and therapeutic relevance. In: Farber EM, Nall LM, Morrhenn V, Jacobs PH (eds) Proceedings of the Forth International Symposium. Stanford, pp 6\u201311"},{"key":"1182_CR27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/archderm.1981.01650070016013","volume":"117","author":"Weinstein","year":"1981","unstructured":"Weinstein GD, McCullough JL, Eaglestein WH et al. (1981) A clinical screening program for topical chemotherapeutic drugs in psoriasis. Arch Dermatol 117: 388\u2013393","journal-title":"Arch Dermatol"},{"key":"1182_CR28","unstructured":"Wendt H, Frosch PJ (1982) Klinisch-pharmakologische Modelle zur Pr\u00fcfung von Coticoidexterna. Karger, Basel M\u00fcnchen Paris London New York Tokyo Sydney"},{"key":"1182_CR29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1396-0296.2004.04044.x","volume":"17","author":"Winterfield","year":"2004","unstructured":"Winterfield LS, Menter A (2004) Infliximab. Dermatol Ther 17: 409\u2013426","journal-title":"Dermatol Ther"},{"key":"1182_CR30","doi-asserted-by":"crossref","unstructured":"Wolff HH, Kreusch JF, Wilhelm KP, Klaus S (1993) The psoriasis plaque test and topical corticosteroids: evaluation by computerized laser profilometry. In: Korting HC, Maibach HI (eds) Topical glucocorticosteroids with increased benefit\/risk ratio. Karger, Basel, pp 107\u2013113","DOI":"10.1159\/000422369"},{"key":"1182_CR31","first-page":"620","volume":"172","author":"Wozel","year":"1986","unstructured":"Wozel G, Barth J (1986) Fluocinolonacetonid und Psoriasis \u2013 kontinuierliche oder alternierende Therapie? Dermatol Monatsschr 172: 620\u2013623","journal-title":"Dermatol Monatsschr"},{"key":"1182_CR32","first-page":"2279","volume":"44","author":"Wozel","year":"1989","unstructured":"Wozel G, Barth J (1989) Untersuchungen zur Wirksamkeit von topischer Corticosteroidkombination bei Psoriasis. Z Klien Med 44: 2279\u20132281","journal-title":"Z Klien Med"},{"key":"1182_CR33","first-page":"550","volume":"172","author":"Wozel","year":"1986","unstructured":"Wozel G. Barth J (1986) Vergleichende Untersuchungen \u00fcber die Wirksamkeit topischer Steroide bei Psoriasis. Dermatol Monatsschr 172: 550\u2013553","journal-title":"Dermatol Monatsschr"},{"key":"1182_CR34","first-page":"155","volume":"20","author":"Wozel","year":"1994","unstructured":"Wozel G (1994) Effektivit\u00e4t der Kombinationsbehandlung mit Calcipotriol und Fluocinolonacetonid im Psoriasis-Plaque-Test. Akt Dermatol 20: 155\u2013158","journal-title":"Akt Dermatol"},{"key":"1182_CR35","first-page":"209","volume":"179","author":"Wozel","year":"1993","unstructured":"Wozel G (1993) Einsch\u00e4tzung von Calcipotriol (MC 903) im Psoriasis-Plaque-Test. Dermatol Monatsschr 179: 209\u2013211","journal-title":"Dermatol Monatsschr"},{"key":"1182_CR36","unstructured":"Wrench R (1985) Assessing drugs for psoriasiform diseases and their antiparakeratotic mechanisms using the mouse tail test. In: Maibach HI, Lowe NJ (eds) Models in dermatology. Karger, Basel, pp 76\u201391"},{"key":"1182_CR37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nature03963","volume":"437","author":"Zenz","year":"2005","unstructured":"Zenz R, Eferl R, Kenner L et al. (2005) Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437: 369\u2013375","journal-title":"Nature"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1182-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-006-1182-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1182-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T12:15:42Z","timestamp":1707135342000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-006-1182-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["1182"],"URL":"https:\/\/doi.org\/10.1007\/s00105-006-1182-z","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}